Gilead Sciences Inc
Change company Symbol lookup
Select an option...
GILD Gilead Sciences Inc
EGHT 8x8 Inc
REGI Renewable Energy Group Inc
MCK Mckesson Corp
CNBX Cannabics Pharmaceuticals Inc
BLK BlackRock Inc
FNMA Federal National Mortgage Association
MPW Medical Properties Trust Inc
PSXP Phillips 66 Partners LP
EQ Equillium Inc
Go

Health Care : Biotechnology | Large Cap Value
Company profile

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.

Closing Price
$58.15
Day's Change
-0.38 (-0.65%)
Bid
--
Ask
--
B/A Size
--
Day's High
58.58
Day's Low
57.18
Volume
(Average)
Volume:
11,871,686

10-day average volume:
12,568,205
11,871,686

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Sale of Immunomedics to Gilead Sciences

11:42 am ET September 14, 2020 (Newsfile) Print

New York, New York--(Newsfile Corp. - September 14, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/7091/63751_27c83c3644572b8a_001full.jpg



To view an enhanced version of this graphic, please visit:

https://orders.newsfilecorp.com/files/7091/63751_27c83c3644572b8a_001full.jpg

To: All Persons or Entities who purchased Immunomedics, Inc. ("Immunomedics" or the "Company") (NASDAQ: IMMU) stock prior to September 13, 2020.

You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Immunomedics toGilead Sciences, Inc. ("Gilead") (NASDAQ: GILD). Under the terms of the deal, Gilead will acquire Immunomedics for $88.00 per share in cash.To learn more about the action and your rights, go to:

https://www.zlk.com/mna2/immunomedics-inc-information-request-form

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.

The Immunomedics merger investigation concerns whether the Board of Immunomedics has harmed stockholders by agreeing to enter into this transaction and whether all material facts have been properly disclosed to stockholders.

Levi & Korsinsky is a nationally recognized firm with offices in New York, Connecticut, California, and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

55 Broadway, 10th Floor

New York, NY 10006

Tel: (212) 363-7500

Fax: (212) 363-7171

www.zlk.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/63751

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.